AVITA MedicalRCEL +0.64%66 Piotroski F-Score is 3 as of Jun. 24, 2026, which is at its 10-year median of 3.00. GuruFocus rates RCEL with a GF Score™ of 66/100 and a GF Value™ of $10.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 805 Medical Devices & Instruments companies, AVITA Medical ranks worse than 77.02% on this metric.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
AVITA Medical has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for AVITA Medical's Piotroski F-Score or its related term are showing as below:
RCEL'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 3 Max: 5
Current: 3
During the past 13 years, the highest Piotroski F-Score of AVITA Medical was 5. The lowest was 1. And the median was 3.
AVITA Medical (NAS:RCEL) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
AVITA Medical Piotroski F-Score Related Terms
AVITA Medical Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for AVITA Medical's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RCEL vs NNOX, MXCT, SNWV: Piotroski F-Score Comparison
For the Medical Devices subindustry, AVITA Medical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where AVITA Medical's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
AVITA Medical's current Net Income (TTM) was -45.34.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
AVITA Medical's return on assets of this year was -0.65183449. AVITA Medical's return on assets of last year was -0.58580216.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
AVITA Medical's gearing of this year was 0.03308792. AVITA Medical's gearing of last year was 0.5303291.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
AVITA Medical's current ratio of this year was 0.47467415. AVITA Medical's current ratio of last year was 2.08951908.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
AVITA Medical's number of shares in issue this year was 30.541. AVITA Medical's number of shares in issue last year was 26.254.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
AVITA Medical's gross margin of this year was 0.81363171. AVITA Medical's gross margin of last year was 0.85467688.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
AVITA Medical's asset turnover of this year was 1.04011156. AVITA Medical's asset turnover of last year was 0.73588277.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
0
+
0
+
0
+
1
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
AVITA Medical has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
AVITA Medical (RCEL) has a Piotroski F-Score of 3 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on AVITA Medical and its competitors. This is near median its historical median of 3.00. Over the past decade, AVITA Medical's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, AVITA Medical ranks #620 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 77%.
Is AVITA Medical's Piotroski F-Score too high?
AVITA Medical's current Piotroski F-Score of 3 is near median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. AVITA Medical's value of 3 is 40% below this industry median. Based on the distribution chart, AVITA Medical ranks #620 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AVITA Medical has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Piotroski F-Score compare to NNOX and MXCT?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #620 out of 805 companies for Piotroski F-Score. This places AVITA Medical in the lower half of its industry. The industry median Piotroski F-Score is 5.00. AVITA Medical's value of 3 is 40% below this benchmark. Historically, AVITA Medical's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, AVITA Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AVITA Medical's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on AVITA Medical and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current Piotroski F-Score is 3, which is near median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (RCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $10.78, compared to a current price of $3.95 — trading 63.4% below its estimated fair value. The current Piotroski F-Score is 3, which is near median its 10-year median of 3.00 and 40% below the Medical Devices & Instruments industry median of 5.00. AVITA Medical's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For AVITA Medical (RCEL), the current Piotroski F-Score is 3 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (RCEL) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued.
The current stock price of $3.95 is trading 63.4% below its estimated GF Value™ of $10.78.
GuruFocus considers AVITA Medical to be Possible Value Trap.
Key valuation signals for RCEL:
Piotroski F-Score: 3 (near median its 10-year median of 3.00)
GF Value™: $10.78 vs. price of $3.95 (63.4% below fair value)
Industry Position: 40% below the Medical Devices & Instruments median (#620 of 805)
No single metric tells the full story. See the RCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
66GF Score
Get the complete analysis for RCEL
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RCEL has been successfully added to your 
